





Smith-Lemli-Opitz syndrome from an international perspective

PD Dr. Dorothea Haas



Lisa – how it all started...

- Feeding difficulties
- Slight developmental delay
- Muscular hypotonia trunc
- Muscular hypertonia extremities
- Small head and peculiar face
- Deformed feet
- Syndactyly toes 2 + 3






Some explanations

- syndrome: symptoms not correlated with each other but associated with a specific disorder
- dysmorphic feature, dysmorphism: difference of body structure



Smith-Lemli-Opitz syndrome


- First described in 1964
- 3 boys with
 - Developmental delay
 - Feeding difficulties
 - Failure to thrive
 - Specific dysmorphic features



A newly recognized syndrome of multiple congenital anomalies

Three unrelated male children have been found to have a strikingly similar pattern of multiple congenital anomalies which suggests a common etiology. In addition to relative microcephaly with mental retardation and hypertonicity, these patients have incomplete development of the external genitals and abnormalities of the face, hands, and feet. Congenital pyloric stenosis was present in two of them. No chromosomal abnormality was found and the cause remains obscure though the apparent occurrence of the same condition in a deceased sibling of one of the patients suggests a genetic determination.


David W. Smith, M.D.,* Luc Lemli, M.D., and John M. Opitz, M.D. MADISON, WIS.





Biochemical abnormalities in SLOS

- 1993/1994 M. Irons / S. Tint
- Biochemical abnormalities in blood of 5 patients with SLOS:
 - Low concentration of cholesterol
 - Elevated concentration of 7dehydrocholesterol






Irons et al., Lancet 1993

Tint et al., NEJM 1994




SLOS is caused by a defect of cholesterol synthesis






Cholesterol functions

- Structural element of membranes and myelin (insulation of nerves)
- Important component of
 - Caveolae and lipid rafts (intracellular transfer)
- Precursor for the synthesis of
 - Bile acids
 - Steroid hormones
 - Neurosteroids
 - Embryonic signalling proteins
- Biosynthesis pathway important for
 - Glycosylation
 - Translation of proteins
 - Differentiation of cells
 - Mitochondrial electron transfer









SLOS – malformations due to intrauterine cholesterol deficiency

- Brain: midline defects (37 %)
- Cleft palate (47 %)
- Heart: ASD, VSD (54 %)
- Kidney: hypoplasia, ectopia, cysts, malformation of urinary tract (43 %)
- Genital: hypospadia, undescended testicles (65 %)
- Skeletal: foot deformity, redundant fingers or toes (48 %), syndactyly
 2/3 (95 %)

Kelley, Hennekam J Med Genet 2000




Haas, Mohnike, Robbin (Hrsg) Mabuse-Verlag 2013





Caruso et al. Neuroradiology 2004



Solomon et al. GeneReviews 2000

Genetics

Inheritance

Autosomal-recessive - possible combinations



Supported by $\P{\bf NUTRICIA}$ as a service to metabolic medicine

Written by Haas & Burgard 16



Frequency and distribution of SLOS

- Incidence 1:10.000 to 1:60.000 newborns in Europe
- Most frequent in Eastern Europe (Czech Republic)
- Less frequent in Asian and African populations



SLOS - Variability of presentation

Severe phenotype

- Malformation of internal organs
- Persistent severe feeding difficulties
- High risk for severe infections
- Severe cognitive impairment
- Behavioual problems are not prominent

Moderate phenotype


- Minimal or no organ malformations
- Transitory feeding difficulties
- No infections
- Mild intellectual impairment
- Behavioural abnormalities (sometimes severe!)

In Germany there are many less severely affected patients Determination of severity

- Amount of residual DHCR7 enzyme activity
- Type of mutation



Some basics on genetics



mons.wikimedia.org/w/index.php?curid=39441809

Missense mutation:

GAAGCCAUG → Glu – Ala – Met

 $GAAGUCAUG \rightarrow Glu - Val - Met$

Insertion:

GAAGCCAUG → Glu – Ala – Met

GAAGCUCAUG → Glu – Ala – His -

Deletion:


 $GAAGCAUGA \rightarrow Glu - Ala - Met$

 $GAAGCAUGA \rightarrow Glu - Ala - Stop$



SLOS genetics

- DHCR7 gene maps to chromosome 11q13.2–13.5
- Consists of nine exons
- >200 different pathogenic *DHCR7* variants
- Most common mutation c.964–1G>C
- disrupts the joining of exons 8 + 9
- insertion of 134 nucleotides
- "Nonsense" mutation
- Complete loss of enzyme activity




Moebius Proc Natl Acad Sci 1998; Waterham Am J Med Genet C 2012; Witsch-Baumgartner Am J Human Genet 2000; Ciara Clin Genet 2004;



SLOS – craniofacial characteristics

- Microcephaly small head
- Ptosis drooping of upper eylids
- Anteverted nostrils
- Microretrognathia small and recessed jaw
- Bitemporal narrowing
- High arched palate
- Midline cleft palate
- Tent-shaped mouth
- Low set ears



A newly recognized syndrome of multiple congenital anomalies

Three unrelated male children have been found to have a strikingly similar pattern of multiple congenital anomalies which suggests a common etiology. In addition to relative microcephaly with mental retardation and hypertonicity, these patients have incomplete development of the external genitals and abnormalities of the face, hands, and feet. Congenital pyloric stenois was present in two of them. No chromosomal abnormality was found and the cause remains obscure though the apparent occurrence of the same condition in a deceased sibling of one of the patients suggests a genetic determination.

David W. Smith, M.D.,* Luc Lemli, M.D., and John M. Opitz, M.D.

MADISON, WIS.



SLOS – skeletal abnormalities

- Syndactyly toes 2/3
- Postaxial polydactyly
- Short, proximally placed thumbs
- Clinodactyly/brachydactyly

- Various foot deformities
- limb shortening

















SLOS – CNS malformations

- Corpus callosum agenesia / hypoplasia
- Enlarged ventricles
- Cerebellar hypoplasia
- Disturbed neuronal migration
- Various forms of holoprosencephaly
- Strucutral epilepsy is possible, however, SLOS is not typically associated with seizures



Caruso et al. Neuroradiology 2004



Solomon et al. GeneReviews 2000



SLOS – genital anomalies

Male patients

- Maldescensus testes
- Hypospadias
- Micropenis
- Genital ambiguity







Female patients

- Mostly normal
- Hypoplasia labia majora and minora
- Puberty premature / delayed
- Normal fertility one pregnancy published

Ellingson Clin Genet 2014





SLOS – cardiovascular anomalies

Frequently endocardial cushion defects

- Atrial septal defect
- Ventricular septal defect
- Patent ductus arteriosus (at term)

Hypoplastic left heart
Persistent pulmonary hypertension








SLOS – renal and adrenal problems

Kidney and urinary tract

- Renal hypo-/ aplasia
- Renal cysts
- Hydronephrosis
- Renal ectopia
- Urinary tract abnormalties
- Arterial hypertension



Adrenal function

- Severely affected patients: adrenal insufficiency
- Abnormal cortisol response to stress (surgery, infections)
- Adrenal insufficiency can lead to death

Bianconi Am J Med Genet 2011; Donoghue J Ped Endocr Metab 2018




SLOS – gastrointestinal problems

Structural problems

- Pyloric stenosis
- Aganglionosis (Hirschsprung disease)
- Anal atresia

Hepatic complications

- Cholestatic hepatopathy
- Liver cirrhosis



Functional problems

- Feeding difficulties
- Intestinal dysmotility (frequent vomiting)
- Food allergies
- Oral hypersensitivity
- Swallowing problems
- Tube feeding often necessary to ensure adequate caloric intake



SLOS - nutrition



https://www.spiegel.de


Caloric intake

- Normal weight: according to reference values for healthy children
- Weight < P3: add 20 %
- Weight > height: reduce 10-30 %



SLOS – growth failure

- 48 male, 35 female SLOS patients, 0-16 y
- Growth 2 SD
- Linear opposed to exponential growth in early childhood
- Supplemental nutrition will not result in improved growth



Lee Am J Med Genet A 2012



Development and behavioural abnormalities

Development

- Delayed psychomotor development
- Gross motor development more affected than fine motor
- Expressive language more impaired than receptive language
- Cognitive impairment:
 - 1/3 severe to profound intellectual disability

Behaviour

- Hyperactivity
- Hypersensitivity to external stimuli
- Impulse control disorder
- Aggressive and autoagressive behaviour
- Self-injury
- Autistic features (51-71 %)
- Abnormal sleep pattern
 - Sleep apnea

Thurm J Neurodev Disord 2016; Diaz-Stransky Am J Med Genet C 2012




SLOS treatment



Cholesterol supplementation

- Blood cholesterol concentration ↑
- Weight and growth 个
- Photosensitivity ↓
- Frequency of infections ↓
- Tactile defensiveness ↓
- Improves behaviour (?)
- does not pass blood-brain barrier, no effect on intrinsic cognitive abilities

Serum cholesterol concentration



Haas JIMD 2007; Irons Am J Med Genet 1997; Nwokoro Am J Med Genet 1997; Azurdia Br Dermatol 2001; Tierney Am J Med Genet 2010; Sikora: J Pediatr 2004



Cholesterol supplementation

Dosage

- Children 100-200 mg/kg/d
- Adults 3-4 g/d (higher dosages are not absorbed)

Preparation:

- Egg yolks (1 yolk = 180 220 mg cholesterol)
- Pure powder or crystalline cholesterol (in Germany not approved for clinical use)
 - Sonic Cholesterol seems to be a suitable product (no personal experience)
- Cholesterol preparations (enriched with sucrose or fat)
- Powder should be dissolved in fat (butter, cream, oil) to ensure enteral absorption
- Tube feeding: dissolve powder in oil or cream and mix this with part of the tube feed.



Sucrose Cholesterol



https://magazin.bodychange.de



Cholesterol Soy oil Vitamin C + E




Cholesterol



Simvastatin

- Passes blood-brain-barrier
- HMG-CoA reductase ↓
- DHCR7 expression 个
- Cell culture: Rapid death of cells with null mutations
- 7-DHC ↓, (7+8-DHC)/Chol ↓
- Irritability ↓
- Side effects: CK and liver enzymes ↑
- Deterioration of behaviour and sleep problems



Jira: J Lipid Res 2000; Wassif: Mol Genet Metab 2005; Haas: JIMD 2007; Wassif: Genet Med 2017



Heidelberg Simvastatin protocol



https://www.dr.maxi.com

- Only in mildly/moderately affected patients ratio (7+8-DHC)/Cholesterol < 1
- Normal CK and liver enzymes
- Start with 0.5 mg/kg b.i.d, increase to 1 mg/kg/d after 4 weeks if CK and liver enzymes are still normal
- Maximal dosage: 30-40 mg/d
- Reliable contraception in postpubertal girls



Treatment of behavioural and sleep problems

- Cholesterol supplementation may improve behaviour
- Behavioural interventions may help in patients with mild/moderate cognitive impairment
- Antipsychotic medication (risperidone, melperone) may be necessary in severe cases

Sleep

- Melatonin is effective in pediatric patients
- No deterioration of sterol pattern seen in SLO patients



Antioxidants


- WRED MEAT LYNCH PUMPKIN STRAWBERRIES AND LYNCH PUMPKIN STRAWBERRIES PROMPTION OF THE PUMPKIN STRAWBERRIES PUMPKIN
 - https://www.wir-essen-gesund.de

- 7-DHC is a very reactive molecule, which is easily converted to oxysterols
- Oxysterols promote cell death, activate inflammation, modulate immune responses
- Oxysterols lead to eye problems in SLOS rat model
- Cholesterol-rich diet enhanced with vitamin C+E prevents eye problems in rats
- Oxysterols are elevated in blood of human SLO patients
- Vit A, C, E + CoQ10 reduce 7-DHC oxysterols in human skin cells
- Clinical trial in Colorado recruiting since 2008 (ClinicalTrials.gov Identifier: NCT01773278)

Korade J Lipid Res 2010; Elias Arch Ophtalmol 2003; Garry: Doc Ophtalmol 2010; Liu: J Lipid Res 2013; Korade: Biol Psychiatry 2014



Bile acids




- Necessary for digestion of fat and resorption of fat soluble vitamins
- Reduced bile acid production in severely affected patients
- Normal bile acid synthesis in mildly affected patients
- No evidence for fat malabsorption or deficiency of fat soluble vitamins in SLO patients
- Supplementation not generally recommended in SLOS
- Cholic acid supplementation may increase cholesterol and reduce DHCs
- Clinical trial not yet recruiting (ClinicalTrials.gov Identifier: NCT03720990)

Natowicz Am J Med Genet 1994 Steiner J Lipid Res 2000 Kelley J Med Genet 2000 Irons Am J Med Genet 1997



Which kind of **medication** do SLOS patients receive in Heidelberg?






Experimental therapeutic options

Liver transplantation

- 19 m old SLO patient, liver cirrhosis
- living-donor split liver transplant from his uncle
- 34 m after transplant: improved fine and gross motor and social skills



Gene therapy - intravenous

- Gene therapy using a recombinant AAV vector in mouse model
- Copies of gene detectable in liver, loss of vector copies over several weeks
- Reduction of serum 7-DHC, no effect on brain

Gene therapy - intrathecal

Partial restoration of sterol levels in CNS, but not in periphery



Ertugrul Exp Clin Transplant 2018; Matabosch J Steroid Biochem Mol Biol 2010; Pasta Mol Genet Metab Rep 2015

Emergency protocol – illness and surgery

Problems

- Risk for adrenal insufficiency
- Airway management (micrognathia, palatal anomalies)
- Cholesterol can only be given perorally
- Emergency regimen depending on severity and intervention
- Consider steroids
- Fresh frozen plasma (FFP) may be a source of cholesterol



Smith-Lemli-Opitz Syndrom / Smith-Lemli-Opitz syndrome

Drohende Entgleisung/

<u>Situationen</u> Schwere hochlieberhalte Infekte, Nüchtemphase/Postaggressionsstoffwechsel bei CP

Komplitationen: Wundheilungsstörungen, Neberniererinsuffizierz (Addison-Krise), AFOS

(Schocklunge) Complications: wound healing problems, adrenal

insufficiency, acute respiratory distress syndron

Maßnahmen/ Teatment:

- Meine Eingriffe: Kontrolle Serumelektrolyte
 Minor interventions: Check serum electrolyte
- größere Eingriffe: zusätzlich fresh fruzen plasma (FFP) 10 ml/kg/d i.v. während Nüchternzeit
- Major interventions: additional fresh frozen plasma (FFF)10 ml/kg bm/d iv during fasting
- Schwer betroffene Patienten (Cholesterol <50 mg/dl): Zusätzlich Hydrocortison-Perfusor 30 mg/m²/d
- Severely affected patients (cholesterol <50 mg/dt): additional hydrocortisone infusion 30 mg/m²/d)

-

Kelley J Med Genet 2000 Boctor Ann Clin Lab Sci 2014



Need to learn more

- SLOS still many uncertainties:
- What is the long-term outcome (40-60-80 years)?
- mild phenotypes
- What is the optimal therapy for which patient?
- Necessity to collect patients of many different centers in European registry
- Heidelberg included SLO patients since June 2019





What can you do?



MetabERN pan-European patient orientated platform

Subnetwork Peroxisomal and lipid related disorders

WHAT IS METABERN

MetabERN represents

69 founding Healthcare Providers (HCPs)

from 18 European Member States and 44 patient organisations MetabERN is endorsed by the Society for the Inborn Errors of Metabolism (SSIEM)







Thank you for your attention!

